slightbourne@noblecapitalmarkets.com, Author at Channelchek

Release – The GEO Group Completes Redemption of All Senior Secured Notes Due 2029

Posted on October 19, 2026October 19, 2026 by [email protected]

October 19, 2026

BOCA RATON, Fla.–(BUSINESS WIRE)–Oct. 19, 2026– The GEO Group, Inc. (NYSE: GEO) (“GEO” or the “Company”) announced today that it completed the redemption of all of the $650,000,000 in outstanding aggregate principal amount of its 8.625%Senior Secured Notes due 2029 (CUSIP Nos. 36162JAG1 and U32352AF0) (the “2029 Senior Secured Notes”) on October 15, 2026 (the “Redemption Date”).

The redemption price for the 2029 Senior Secured Notes was equal to $1,043.13 per $1,000.00 original principal amount, or approximately $678 million, plus any accrued and unpaid interest up to, but excluding, the Redemption Date. The Indenture governing the 2029 Senior Secured Notes has been discharged. Payment of the redemption price for the 2029 Senior Secured Notes was made through the Depository Trust Company.

On October 6, 2026, GEO previously announced the closing of an amendment to the Company’s Amended Credit Agreement to extend the maturity of its $550 million Revolving Credit Facility to July 14, 2031 and to increase the Company’s restricted payments capacity. As of October 19, 2026, GEO had no outstanding borrowings under its Revolving Credit Facility.

Following this amendment and the discharge of the Indenture governing the 2029 Senior Secured Notes, GEO is permitted to make unlimited restricted payments, including share repurchases, under the Amended Credit Agreement, to the extent the Company’s total leverage ratio (as defined therein) calculated on a pro forma basis after giving effect to such restricted payment would be equal to or less than 2.25 to 1.00 and no default exists thereunder. Additionally, under the Indenture governing the Company’s $625 million 10.25% Senior Unsecured Notes due 2031, GEO is permitted to make unlimited restricted payments, including share repurchases, to the extent the Company’s consolidated total leverage ratio (as defined therein) calculated on a pro forma basis after giving effect to such restricted payment would be equal to or less than 2.00 to 1.00 and no default exists thereunder. On October 5, 2026, GEO previously announced that its Board of Directors approved a $750 million increase to the Company’s share repurchase authorization program, which is effective through December 31, 2029, from $500 million to $1.25 billion.

Following the redemption of the 2029 Senior Secured Notes, GEO’s outstanding gross debt totaled $625 million as of October 19, 2026, excluding mortgage debt on the Company’s Headquarters building with current principal balance of approximately $36 million.

About The GEO Group

The GEO Group, Inc. (NYSE: GEO) is a leading diversified government service provider, specializing in design, financing, development, and support services for secure facilities, processing centers, and community reentry centers in the United States, Australia, South Africa, and the United Kingdom. GEO’s diversified services include enhanced in-custody rehabilitation and post-release support through the award-winning GEO Continuum of Care®, secure transportation, electronic monitoring, community-based programs, and correctional health and mental health care. GEO’s worldwide operations include the ownership and/or delivery of support services for 97 facilities totaling approximately 76,000 beds, including idle facilities and projects under development, with a workforce of up to approximately 20,000 employees.

Use of forward-looking statements

This news release may contain “forward-looking statements” within the meaning of Section 21E of the Securities Exchange Act of 1934, as amended, and the U.S. Private Securities Litigation Reform Act of 1995. Readers are cautioned not to place undue reliance on these forward-looking statements and any such forward-looking statements are qualified in their entirety by reference to the cautionary statements and risk factors contained in GEO’s filings with the U.S. Securities and Exchange Commission including its Form 10-K, 10-Q and 8-K reports. All forward-looking statements speak only as of the date of this news release and are based on current expectations and involve a number of assumptions, risks and uncertainties that could cause the actual results to differ materially from such forward-looking statements. Readers are strongly encouraged to read the full cautionary statements and risk factors contained in GEO’s filings with the U.S. Securities and Exchange Commission, including those referenced above. GEO disclaims any obligation to update or revise any forward-looking statements, except as required by law.

View source version on businesswire.com: https://www.businesswire.com/news/home/20261016246329/en/

Pablo E. Paez (866) 301 4436
Executive Vice President, Corporate Relations

Source: The GEO Group, Inc.

Release – NeuroSense Files U.S. Patent Application for Traumatic Brain Injury

Posted on October 19, 2026October 19, 2026 by [email protected]

CAMBRIDGE, Mass., Oct. 19, 2026 /PRNewswire/ — NeuroSense Therapeutics Ltd. (NASDAQ: NRSN) (“NeuroSense” or the “Company”), a late-stage clinical biotechnology company developing treatments for neurodegenerative diseases, today announced that it has filed a patent application with the U.S. Patent and Trademark Office covering methods of treating traumatic brain injury (TBI) and related central nervous system injuries with the combination of ciprofloxacin and celecoxib, the active ingredients of PrimeC.

The application covers the treatment of a broad range of brain injuries, from concussion and mild TBI to moderate and severe TBI, including blast-related injury, as well as their long-term consequences, such as chronic traumatic encephalopathy (CTE). If granted, the patent is expected to provide protection through 2047, subject to any extensions.

Traumatic brain injury (TBI) represents a major global healthcare challenge, affecting millions of people each year. TBI can result from falls, motor vehicle accidents, sports-related injuries and military-related trauma, including blast exposure. Its consequences can extend well beyond the initial event, potentially causing persistent cognitive, physical and behavioral impairment, with substantial burdens on patients, caregivers and healthcare systems. Despite this significant unmet medical need, there are currently no approved disease-modifying therapies specifically targeting the secondary neurological injury associated with TBI.

Following the initial trauma, TBI can trigger complex biological processes, including neuroinflammation, oxidative stress and progressive neuronal damage. Certain mechanisms overlap with pathways implicated in neurodegenerative disorders.

The patent filing also supports NeuroSense’s longer-term strategy of pursuing additional applications for PrimeC beyond its existing development programs. The Company views TBI as an opportunity to broaden PrimeC’s commercial potential and build additional long-term value around its lead asset. While ALS remains NeuroSense’s primary development priority, the Company is evaluating future TBI-focused research and development initiatives, through strategic collaborations, research grants and other non-dilutive funding opportunities.

“While ALS remains our primary focus, we believe PrimeC may have potential across a broader range of neurological conditions that share common underlying disease mechanisms,” said Alon Ben-Noon, Chief Executive Officer of NeuroSense. “TBI is a particularly compelling area given the large affected population, the long-term consequences of brain injury and the lack of approved disease-modifying treatments. This filing strengthens our intellectual property position and creates a foundation for future research, partnerships and non-dilutive funding opportunities, while maintaining our focus on advancing our core ALS program. We look forward to sharing further updates as our clinical and strategic initiatives advance.”

About NeuroSense

NeuroSense Therapeutics is a late-clinical stage biotechnology company developing novel treatments for severe neurodegenerative diseases, including amyotrophic lateral sclerosis (ALS) and Alzheimer’s disease. The Company’s lead product candidate, PrimeC, is a novel oral therapy designed to target multiple key biological pathways underlying disease progression, including neuroinflammation, oxidative stress and dysregulated iron metabolism.

NeuroSense has recently completed analysis of long-term follow-up data from its Phase 2b PARADIGM study in ALS, with results published in JAMA Neurology showing slower functional decline in participants who received PrimeC from study start than in those who initially received placebo. The Company also reported changes across multiple biomarkers associated with ALS, including microRNAs, consistent with PrimeC’s multi-target mechanism of action.

NeuroSense has received clearance from the U.S. Food and Drug Administration (FDA) to initiate its pivotal Phase 3 clinical trial (PARAGON) in ALS, to be conducted primarily in the United States. The Company is working with FDA on an optimized design for the study.

For additional information, we invite you to visit our website and follow us on LinkedIn, YouTube and X. Information that may be important to investors may be routinely posted on our website and these social media channels.

About PrimeC

PrimeC, NeuroSense’s lead drug candidate, is a novel extended-release oral formulation composed of a unique fixed-dose combination of two FDA-approved drugs: ciprofloxacin and celecoxib. PrimeC is designed to target several key mechanisms that contribute to neuron degeneration, inflammation, iron accumulation and impaired ribonucleic acid (“RNA”) regulation, with the potential to inhibit disease progression.

About ALS

Amyotrophic lateral sclerosis (“ALS”) is an incurable neurodegenerative disease that causes progressive paralysis and, typically, death within 3 years of symptoms onset. Every year, more than 5,000 people are diagnosed with ALS in the U.S. alone, with an annual disease burden of $1 billion. The number of people living with ALS is expected to grow by 24% by 2040 in the U.S. and EU.

Forward-Looking Statements

This press release contains “forward-looking statements” that are subject to substantial risks and uncertainties. All statements, other than statements of historical fact, contained in this press release are forward-looking statements. Forward-looking statements contained in this press release may be identified by the use of words such as “anticipate,” “believe,” “contemplate,” “could,” “estimate,” “expect,” “intend,” “seek,” “may,” “might,” “plan,” “potential,” “predict,” “project,” “target,” “aim,” “should,” “will,” “would,” or the negative of these words or other similar expressions, although not all forward-looking statements contain these words. Forward-looking statements are based on NeuroSense Therapeutics’ current expectations and are subject to inherent uncertainties, risks and assumptions that are difficult to predict and include statements regarding the Company’s development program, including for ALS and TBI, the potential issuance, scope and duration of patent protection arising from the Company’s patent application, including expected protection through 2047, subject to any extensions, the potential of PrimeC to treat TBI and related central nervous system injuries, the potential expansion of PrimeC beyond ALS and its potential commercial benefits and long-term value. Further, certain forward-looking statements are based on assumptions as to future events that may not prove to be accurate. The future events and trends may not occur and actual results could differ materially and adversely from those anticipated or implied in the forward-looking statements. These risks include the risk that the patent application will not result in an issued patent or that any patent granted will not provide the Company with the anticipated scope or duration of protection or will be challenged, invalidated or unenforceable; the risk that PrimeC will not demonstrate safety or efficacy in TBI or related conditions; the potential for delay in the timing of the Phase 3 clinical trial (PARAGON) in ALS; the risk that the Company will not be able to obtain financing on acceptable terms, or at all; the risk that the Company will not regain and maintain compliance with the Nasdaq listing requirements; the risk that non-dilutive grant funding for the PARAGON trial will not be awarded or will be delayed; uncertainty regarding outcomes and the timing of current and future clinical trials; the risk that PrimeC will not advance towards later-stage development; timing for reporting data, including from the study of PrimeC in Alzheimer’s disease; that the study will not be successful; and other risks and uncertainties set forth in NeuroSense’s filings with the Securities and Exchange Commission (SEC). You should not rely on these statements as representing our views in the future. More information about the risks and uncertainties affecting NeuroSense is contained under the heading “Risk Factors” in the Annual Report on Form 20-F filed with the Securities and Exchange Commission on March 31, 2026 and NeuroSense’s subsequent filings with the SEC. Forward-looking statements contained in this announcement are made as of this date, and NeuroSense undertakes no duty to update such information except as required under applicable law.

SOURCE NeuroSense

For further information: For further information: Email: [email protected] | Tel: +972-(0)9-799-6183

Merck to Acquire Silence Therapeutics for $1.3 Billion in Major Gene-Silencing Biotech Deal

Posted on October 19, 2026October 19, 2026 by [email protected]

The $20-per-share acquisition represents a 130% premium as Merck expands its rare disease pipeline and strengthens its position in RNA-based medicines.

German pharmaceutical and technology company Merck KGaA has agreed to acquire Silence Therapeutics (NASDAQ: SLN) in an approximately $1.3 billion all-cash transaction, highlighting growing interest in gene-silencing therapies and rare disease treatments. The deal, announced Monday, October 19, offers Silence shareholders $20 per American Depositary Share (ADS), representing a substantial 130% premium to the company’s closing price of $8.68 on Friday.

The acquisition values Silence Therapeutics at approximately $1.3 billion in equity and $1.1 billion in enterprise value. The purchase price also represents an 82% premium to the company’s 30-day volume-weighted average share price, underscoring the strategic value Merck places on its emerging drug pipeline.

At the center of the transaction is divesiran, an experimental RNA-based treatment targeting polycythemia vera, a rare form of blood cancer characterized by the excessive production of red blood cells. The condition can increase the risk of blood clots, strokes, and other serious cardiovascular complications, often requiring patients to undergo regular blood removal procedures to control their red blood cell levels.

Divesiran uses small interfering RNA (siRNA) technology to selectively silence a gene involved in regulating iron metabolism. By limiting iron availability for red blood cell production, the therapy aims to reduce the need for frequent blood removal treatments while improving disease management.

Recent Phase 2 clinical trial results have strengthened the drug’s potential. In the SANRECO study, divesiran achieved an 88% response rate compared with 19% for patients receiving placebo. Patients receiving the experimental therapy also required significantly fewer blood removal procedures, providing encouraging evidence ahead of planned Phase 3 development.

One potential advantage of divesiran is its dosing schedule. The treatment is designed to be administered through an injection once every three months, potentially offering patients a more convenient alternative to therapies requiring more frequent administration.

For Merck, the acquisition represents another step in its strategy to expand into specialized treatments addressing significant unmet medical needs. The company previously acquired SpringWorks Therapeutics in 2025, strengthening its presence in rare diseases and oncology. Adding Silence Therapeutics provides access to a promising late-stage drug candidate and a broader platform for developing RNA-based medicines.

The transaction also highlights the growing importance of gene-silencing technology within the biotechnology industry. Unlike traditional medicines that target proteins after they are produced, siRNA therapies work by reducing the production of specific disease-related proteins, potentially offering more targeted treatment approaches.

For biotechnology investors, the 130% acquisition premium demonstrates how promising clinical data can significantly increase the strategic value of smaller drug developers. Large pharmaceutical companies continue seeking innovative assets to replenish their pipelines, diversify revenue streams, and establish positions in emerging treatment categories.

However, divesiran remains investigational and must successfully complete additional clinical testing before potentially receiving regulatory approval. Its commercial prospects will depend on demonstrating sustained effectiveness, safety, and competitive advantages over existing treatments.

The transaction has received unanimous approval from Silence Therapeutics’ board and is expected to close during the first quarter of 2027, subject to shareholder, regulatory, and court approvals.

The acquisition reinforces a broader trend in biotechnology: pharmaceutical companies are increasingly willing to pay substantial premiums for innovative therapies supported by promising clinical results. As RNA-based medicine continues advancing, smaller biotechnology companies developing differentiated treatments could attract further acquisition interest from larger industry players.

Kodiak Copper Corp. (KDKCF) – Kodiak Extends Ketchan Mineralization, Strengthening Resource Potential

Posted on October 19, 2026October 19, 2026 by [email protected]

Monday, October 19, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Ketchan deposit expands significantly. Kodiak Copper recently reported encouraging results from seven drill holes totaling 1,583 meters at its 100%-owned MPD copper-gold project in British Columbia. Step-out drilling extended the known mineralized envelope at Ketchan by at least 450 meters southeast of its existing 1.4-kilometer resource footprint, increasing the known extent of the mineralized system and supporting potential resource growth.

Near-surface copper-gold mineralization. Hole AG-26-034 intersected 122.5 meters grading 0.41% copper equivalent (CuEq), beginning just 5.5 meters below the surface. Hole AG-26-021 returned 202.5 meters grading 0.20% CuEq, while infill hole AG-26-015 intersected 207.3 meters grading 0.31% CuEq. The results demonstrate mineralization both beyond and within the existing resource boundaries.

Get the Full Report

Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.

First Phosphate Corp. (PHOS) – Advancing Toward Feasibility

Posted on October 19, 2026October 19, 2026 by [email protected]

Monday, October 19, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Significant progress toward development. First Phosphate continues to advance its North American LFP battery materials strategy, supported by its inclusion in a G7-backed critical minerals initiative, international financing interest, accelerated permitting coordination in Quebec, and expanded mineral resources. These developments strengthen the company’s strategic position as Bégin-Lamarche advances toward feasibility.

Strengthening project economics and financing prospects. With the updated mineral resource estimate, indicated mineral resources increased by 378%, providing greater geological confidence for feasibility-level mine planning. Canadian government contributions and potential export credit support from Swiss and Danish agencies could reduce future funding requirements. Management is targeting completion of the Bégin-Lamarche feasibility study in the first quarter of calendar 2027.

Get the Full Report

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Conduent (CNDT) – Conduent Moves To Resolve Major Litigation Overhang

Posted on October 19, 2026October 19, 2026 by [email protected]

Monday, October 19, 2026

Michael Kupinski, Director of Research, Equity Research Analyst, Digital, Media & Technology , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

Reaches $80 million class action settlement. Conduent agreed to settle consolidated class action litigation related to its previously disclosed January 2025 cybersecurity incident. The incident involved unauthorized access to the company’s networks beginning in October 2024 and exposed personal information belonging to approximately 62 million individuals. The agreement remains subject to court approval.

Addresses significant litigation exposure. The settlement seeks to resolve litigation stemming from the cybersecurity incident, including claims involving Conduent and affected clients. Upon final approval, the agreement would release Conduent, its affected clients, and their affected customers from covered claims arising from the incident. We believe the agreement provides greater visibility into a significant legal uncertainty that has weighed on the company’s broader turnaround efforts.

Get the Full Report

This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Kratos Defense & Security (KTOS) – A Tuck-in and Other News

Posted on October 19, 2026October 19, 2026 by [email protected]

Monday, October 19, 2026

Joe Gomes, CFA, Managing Director, Equity Research Analyst, Generalist , Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

A Tuck-in. Last week, Kratos acquired Jetset Airmotive from its founders. Jetset’s MRO operations on PT6A turbine engines complement Kratos’ existing MRO operations conducted through its Oklahoma-based CTS subsidiary. Based on previous such transactions, we believe the acquisition was structured as 50% KTOS shares and 50% cash, which would imply roughly $50 million in total. With an estimated $40-$50 million in revenue and typical 13-14% EBITDA margins, Jetset was purchased for approximately 1x revenue and 9x EBITDA. The acquisition should add about $5+ million to annual EBITDA.

New Contracts. Kratos has been awarded more than $100 million over multiple contracts to develop prototype mission applications and cyber capabilities, providing space intelligence data in support of joint operations across the space and cyberspace domains. The contracts will leverage Kratos’ software products, analytics, and expertise in RF, signal processing, cybersecurity, and software development, establishing a proven technology base that can be adapted and integrated to meet emerging space and cyber mission requirements.

Get the Full Report

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Two Biotech IPOs Raise $350 Million as Investor Appetite for New Drug Developers Rebounds

Posted on October 19, 2026October 19, 2026 by [email protected]

City Therapeutics and Iambic Therapeutics make strong Nasdaq debuts, highlighting renewed interest in RNA-based medicines and AI-powered drug discovery.

The biotechnology IPO market showed fresh signs of momentum last week as City Therapeutics (NASDAQ: CTY) and Iambic Therapeutics (NASDAQ: IAM) raised a combined $350 million in public offerings. Both companies attracted strong investor interest and delivered positive first-day trading performances, suggesting that demand for emerging drug developers may be improving despite broader market volatility.

City Therapeutics, a Cambridge, Massachusetts-based biotechnology company developing RNA interference (RNAi) medicines, raised approximately $200 million through an upsized initial public offering. The company sold 11.1 million shares at $18 each, exceeding its original fundraising target, and began trading on the Nasdaq on October 16.

Shares climbed approximately 24% during their first trading session, closing at $22.40 and giving the company a strong public-market debut.

Founded in 2023, City Therapeutics focuses on RNAi technology, which works by silencing specific genes responsible for producing disease-related proteins. Its lead candidate, CITY-FXI, is undergoing Phase 1 clinical testing for thromboembolic diseases, conditions involving potentially dangerous blood clots.

The company’s broader pipeline includes CITY-RBP4, targeting Stargardt disease and other retinal disorders, and CITY-TFR2, being developed for anemia associated with chronic diseases. The IPO proceeds will help advance these programs through clinical development.

Meanwhile, San Diego-based Iambic Therapeutics raised $150 million through the sale of approximately 9.4 million shares priced at $16 each. The company began trading on October 15 under the ticker IAM, with shares gaining approximately 13% during their first session.

Iambic represents a different segment of biotechnology innovation, combining artificial intelligence with automated laboratory experimentation to accelerate drug discovery.

Its proprietary technology uses AI models to analyze molecular structures, predict drug behavior, and identify promising therapeutic candidates. The company believes this approach can reduce the time and resources traditionally required to discover and develop new medicines.

Iambic’s lead clinical candidate, IAM1363, is an experimental cancer treatment discovered using its AI-powered platform. The company also maintains a pipeline of additional oncology programs and partnerships with established pharmaceutical companies.

Investor interest in Iambic was supported by prominent institutional backers, including ARK Investment Management and Duquesne Family Office, which indicated interest in purchasing up to $60 million of shares in the offering. Nvidia has also established an investment and technology relationship with the company.

The successful debuts arrive during a period when biotechnology companies have faced challenging financing conditions, with higher capital costs and investor caution limiting access to public markets.

However, these offerings suggest investors remain willing to support companies with differentiated technologies, promising drug pipelines, and credible development strategies.

The contrasting approaches of City Therapeutics and Iambic also highlight two important investment themes. RNA-based therapies are expanding the range of diseases that can potentially be treated through targeted genetic mechanisms, while artificial intelligence is creating new opportunities to improve drug discovery efficiency.

Still, both companies remain clinical-stage developers, meaning their long-term success depends on achieving favorable clinical trial results, securing regulatory approvals, and eventually commercializing their treatments.

For investors, the combined $350 million raised and positive trading debuts provide encouraging evidence that the biotechnology IPO market may be regaining momentum. Whether that momentum continues will depend on broader market conditions, future clinical milestones, and the performance of newly listed companies.

The strong reception for City Therapeutics and Iambic suggests that innovative biotechnology remains an attractive investment opportunity, particularly where emerging technologies offer the potential to address significant unmet medical needs.

The contrasting approaches of City Therapeutics and Iambic highlight growing investor interest in innovative drug development platforms. That interest extends to smaller publicly traded biotechnology companies advancing novel treatments, including Ocugen (NASDAQ: OCGN), which is developing gene therapies for inherited retinal diseases, and MAIA Biotechnology (NYSE American: MAIA), which is advancing its investigational telomere-targeting cancer treatment, ateganosine. While these companies pursue different scientific approaches, they reflect the broader investment focus on targeted therapies addressing unmet medical needs. Meanwhile, Merck KGaA’s $1.3 billion acquisition of Silence Therapeutics further underscores the strategic value pharmaceutical companies are placing on emerging RNA-based medicines.

Why Did Palantir Stock Drop? $260 Billion Software Selloff Raises AI Valuation Concerns

Posted on October 19, 2026October 19, 2026 by [email protected]

Palantir Technologies (NASDAQ: PLTR) shares fell approximately 7% during the October 16 trading session, wiping out roughly $34 billion in market value as investors reassessed artificial intelligence valuations and the outlook for high-growth software companies. The decline came amid a broader technology selloff that erased more than $260 billion in market capitalization across the software industry.

The sharp drop followed a strong rally that pushed Palantir stock close to $213 earlier in the week. Despite the company’s rapid revenue growth and strong demand for its AI-powered platforms, investors are increasingly questioning whether elevated valuations can be sustained amid economic uncertainty, rising competition, and concerns about the long-term profitability of artificial intelligence investments.

Why Did Palantir Stock Drop?

Palantir’s decline reflects a combination of profit-taking, elevated valuation concerns, and broader weakness in technology stocks.

After breaking above its previous record, the stock quickly reversed direction, raising concerns about a potential “bull trap,” a market pattern in which shares break above a resistance level before falling back.

Investors have been closely watching the $188.15 price level, which would represent a correction of more than 10% from Palantir’s recent record closing price.

Valuation remains a central concern. Despite reporting a 93% year-over-year increase in second-quarter revenue, Palantir has traded at approximately 55 times projected annual revenue, a substantial premium that leaves little room for disappointing financial results.

A $260 Billion Software Selloff Hits Technology Stocks

Palantir’s decline was part of a much broader retreat across the software sector.

Of 45 major software companies tracked in one industry basket, 43 traded lower during Friday’s session, with 15 declining by at least 5%.

Microsoft (NASDAQ: MSFT) lost approximately $83 billion in market capitalization, while ServiceNow (NYSE: NOW) reversed an earlier gain and declined more than 5%. Salesforce (NYSE: CRM) also fell, and Twilio (NYSE: TWLO) experienced a double-digit percentage drop.

The iShares Expanded Tech-Software Sector ETF (IGV) declined nearly 5%, underscoring the widespread selling pressure across the industry.

Cybersecurity stocks also faced significant losses. The First Trust Nasdaq Cybersecurity ETF (CIBR) declined approximately 10% for the week, while Palo Alto Networks (NASDAQ: PANW) and CrowdStrike (NASDAQ: CRWD) each fell roughly 18%.

Are AI Stock Valuations Becoming Too Expensive?

The selloff highlights growing concerns about how investors value companies benefiting from the artificial intelligence boom.

Although AI adoption has created substantial growth opportunities, some investors are questioning whether current stock prices adequately reflect the costs, competitive pressures, and uncertainty associated with developing and commercializing AI technologies.

Palantir’s reported 93% second-quarter revenue growth demonstrates strong demand for its software platforms. However, its premium valuation means investors may expect continued exceptional performance.

At the same time, emerging AI technologies could disrupt traditional software business models, potentially increasing competition and placing pressure on profit margins.

These concerns are affecting companies across the software industry, not just businesses directly associated with artificial intelligence.

How Inflation and Interest Rates Affect AI Stocks

Macroeconomic uncertainty is also contributing to volatility in technology shares.

Persistent inflation and questions surrounding Federal Reserve interest rate policy have made investors more cautious about high-growth companies trading at elevated valuations.

Higher interest rates can reduce the present value investors assign to future earnings, placing additional pressure on stocks whose valuations depend heavily on long-term growth expectations.

For companies such as Palantir, the combination of high investor expectations and changing economic conditions can amplify share-price movements even when underlying business performance remains strong.

What Should Investors Watch Next for Palantir Stock?

Palantir’s recent decline highlights the distinction between strong operational performance and the valuation investors are willing to pay for future growth.

Several factors could influence sentiment toward Palantir and the broader AI software sector, including continued revenue growth, profitability, customer demand, competitive developments, and changes in interest rate expectations.

The $260 billion software selloff does not necessarily signal the end of the artificial intelligence investment cycle. Instead, it suggests investors are becoming more selective as the industry matures.

For Palantir and other AI-focused software companies, sustaining investor confidence may increasingly depend on demonstrating that strong demand can translate into consistent revenue growth, durable profitability, and long-term shareholder value.

Release – NN, Inc. Enters Cable Assembly & Harness Business

Posted on October 16, 2026October 16, 2026 by [email protected]

CHARLOTTE, N.C., Oct. 16, 2026 (GLOBE NEWSWIRE) — NN, Inc. (“NN” or the “Company”) (NASDAQ: NNBR), an entrepreneurial growth company that engineers and manufactures high-precision components and assemblies, today announced the launch of a new Cable Assembly and Wire Harness product line and business. This new business startup represents NN’s fourth unique new product line introduced by the Company during 2026.

This new Cable Assembly and Wire Harness product line adds to NN’s growth program that targets Data Center, Defense, Electric Grid, Medical and High-Value Vehicle systems end markets. The product line includes engineered wiring, cable assembly, bus-bar assemblies, and box-build solutions. Production will be centered in Cd. Juarez, Chihuahua Mexico.

This new product line leverages NN’s vertical integration in precision machining, precision stamping and complex engineered components. It also leverages the existing management team’s historical experience in building and leading successful cable assembly and wire harness operations. This will enable NN to offer customers a higher level of value with cohesive electrical and electromechanical solutions.

The new Cable Assembly and Wire Harness Solutions business will feature advanced automated wire cutting, stripping, crimping, and termination equipment, complemented by digital work instructions, virtual assembly boards, and carousel-based assembly systems. Dedicated engineering and rapid prototyping capabilities will help accelerate project timelines, supporting customers from concept development and electrical architecture through detailed design, validation, and production readiness. Flexible production cells for low- and high-voltage applications, along with box-build capabilities, will enable NN to serve customers across a range of production volumes. Combined with NN’s rapid prototyping and flexible manufacturing processes, these capabilities will help shorten project turnaround times, accelerate product development, and enable customers to move efficiently from prototype to full-scale production.

NN’s first new product line introduced in 2026 was for the Data Center liquid cooling connector market. The second new product line was for the Medical market and aimed at producing components for automated surgery equipment, and the third new product line focuses on the Defense market to produce titanium firearm and weapon assemblies.

Tim Erro, NN’s Chief Commercial Officer will be the General Manager of the new business. Moe Farhat will be the Chief Technology Officer, Raul Gutierrez will be the Sales Manager, and Luis Gomez will be the Juarez Plant Manager.

Harold Bevis, President and Chief Executive Officer of NN commented, “NN is committed to strong growth in our targeted end markets, and the launch of this new product line is another addition. We have the right team to lead this new product line and business. We are bringing together precision components, interconnect expertise, and higher-level assembly capabilities and providing customers a powerful and simplified solution set from a single manufacturing partner. This is an exciting additional growth step and we look forward to discussing our results in this new product area.”

About NN, Inc.

NN, Inc. (NASDAQ: NNBR) is an entrepreneurial manufacturing company specializing in manufacturing micron-tolerance precision metal componentry for high-growth end markets, especially Data Center, Electric Grid, Medical, Defense, and High-Value Vehicle systems. Founded in 1980, NN serves over 700 customers on 4 continents through its 2,700 person workforce operating out of 28 global plants. This footprint enables rapid innovation and globally scaled solutions. For more information, visit nninc.com.

Forward Looking Statements

This press release may contain forward-looking statements regarding our business, operations, and financial performance. Such statements are based on current expectations and assumptions that are subject to a number of risks and uncertainties. Actual results could differ materially. Please refer to our most recently filed Form 10-K and our Form 10-Q for the period following that Form 10-K, including the risk factors described therein. We undertake no obligation to update any forward-looking statement, except as required by law. Given these risks and uncertainties, investors are cautioned not to place undue reliance on such forward-looking statements.

Investor Relations:
Joe Caminiti
[email protected]
312-445-2870

Tectonic Metals Inc. (TETOF) – High-Grade Results Strengthen Flat’s Resource Potential

Posted on October 16, 2026October 16, 2026 by [email protected]

Friday, October 16, 2026

Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.

Refer to the full report for the price target, fundamental analysis, and rating.

High-grade results strengthen exploration outlook. Tectonic Metals reported encouraging results from 19 drill holes at its Flat Gold Project in Alaska. At the Alpha Bowl target, drilling intersected 2.41 grams per tonne (g/t) gold over 59.44 meters, including 11.82 g/t over 10.67 meters and 39.96 g/t over 3.05 meters, within a broader interval of 1.86 g/t over 80.77 meters beginning at the surface. The results strengthen the potential for a large, near-surface gold system containing higher-grade zones.

Alpha Bowl emerges as a priority target. Alpha Bowl extends approximately 820 meters along strike and 600 meters in width, with mineralization encountered beyond 300 meters of vertical depth. Recent and historical drilling demonstrate gold mineralization across multiple locations, with higher-grade intersections suggesting opportunities to enhance future resource quality. Drilling is evaluating mineralization continuity and expansion potential, with several holes awaiting assays.

Get the Full Report

This Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).

Proofpoint to Buy Varonis (VRNS) for $6.3B in Major AI Security Deal

Posted on October 16, 2026October 16, 2026 by [email protected]

Cybersecurity giant Proofpoint has announced plans to acquire Varonis Systems (NASDAQ: VRNS) in an approximately $6.3 billion all-cash transaction, marking one of the largest cybersecurity deals of 2026. The acquisition reflects growing demand for advanced data protection as artificial intelligence transforms how businesses operate and manage sensitive information.

Announced October 15, the agreement will bring together Proofpoint’s expertise in email security, threat prevention, and human-centric cybersecurity with Varonis’ capabilities in data security, access management, and AI protection. The combined company aims to create a comprehensive platform capable of addressing increasingly sophisticated cyber threats.

Under the agreement, Varonis shareholders will receive $49.75 per share in cash, representing a 52% premium over the company’s June 22 closing price of $32.71, before initial acquisition speculation emerged.

The transaction values Varonis at approximately 8.4 times trailing twelve-month revenue and 53 times free cash flow, demonstrating the substantial valuations investors are assigning to companies positioned within the rapidly expanding AI security market.

Proofpoint, owned by private equity firm Thoma Bravo, will finance the transaction through committed equity and debt financing. Ontario Teachers’ Pension Plan will also invest in Proofpoint as part of the deal.

The acquisition is expected to close during the first half of 2027, pending shareholder and regulatory approvals. Following completion, Varonis will become privately held and its shares will cease trading on the Nasdaq.

The acquisition comes as businesses increasingly integrate generative AI and autonomous AI agents into everyday operations, creating new vulnerabilities involving sensitive corporate information.

AI-powered systems can access enormous amounts of enterprise data, raising concerns about unauthorized access, information leakage, and increasingly sophisticated cyberattacks.

Varonis specializes in identifying sensitive data, monitoring access permissions, and detecting suspicious activity across cloud and enterprise environments. Proofpoint brings established capabilities in protecting employees, communications, and digital interactions.

Combining these technologies could allow organizations to better understand who—or what—can access critical information while strengthening defenses against emerging AI-driven threats.

The companies expect their combined operations to serve more than 16,000 enterprises and millions of organizations worldwide.

The transaction underscores a broader consolidation trend across cybersecurity, where larger providers are acquiring specialized technologies to deliver integrated security platforms.

For investors, the acquisition highlights the strategic importance of data protection as enterprise AI adoption accelerates.

Rather than relying on numerous independent security vendors, businesses are increasingly seeking unified solutions capable of protecting employees, cloud infrastructure, sensitive information, and AI applications.

This shift could create additional acquisition opportunities for smaller cybersecurity companies offering differentiated technologies in data governance, identity protection, and AI threat detection.

However, premium valuations also introduce execution risks. Proofpoint must successfully integrate Varonis’ technology, retain customers, and demonstrate that its expanded platform delivers meaningful competitive advantages.

Proofpoint’s $6.3 billion acquisition of Varonis illustrates how artificial intelligence is reshaping cybersecurity investment priorities.

As enterprises deploy increasingly autonomous AI systems, protecting the information those systems access is becoming essential.

For the broader technology sector, the deal reinforces a significant investment theme: the growth of artificial intelligence is creating opportunities not only for companies developing AI, but also for those securing it.

Whether the acquisition delivers its anticipated benefits will depend on successful integration and continued enterprise demand for comprehensive AI security solutions.

Why Are AI Stocks Falling? Nvidia and CoreWeave Slide as Investors Question AI Spending

Posted on October 16, 2026October 19, 2026 by [email protected]

Nvidia (NASDAQ: NVDA), CoreWeave (NASDAQ: CRWV), and other artificial intelligence stocks came under selling pressure on October 15, 2026, as investors raised concerns about soaring AI infrastructure costs, debt financing, and whether massive technology investments will generate sustainable profits. Nvidia shares fell approximately 3% during Thursday morning trading, while CoreWeave extended losses following a sharp decline the previous session.

The broader AI stock selloff has affected semiconductor manufacturers, cloud computing providers, and data center companies. Despite continued demand for artificial intelligence technology, investors are becoming increasingly concerned about the financial risks associated with funding the industry’s rapid expansion.

Why Is Nvidia Stock Falling?

Nvidia shares declined alongside other semiconductor stocks as investors reassessed the sustainability of spending on artificial intelligence infrastructure.

The company supplies advanced processors used to train and operate AI models, making its business closely connected to spending by major technology companies and cloud computing providers.

Although demand for AI computing remains substantial, concerns about rising infrastructure costs and the financial health of companies investing heavily in AI have weighed on investor sentiment.

Advanced Micro Devices (NASDAQ: AMD) and Micron Technology (NASDAQ: MU) also recorded declines during Thursday’s trading session.

The Philadelphia Semiconductor Index lost more than $1.6 trillion in market capitalization over six trading sessions, illustrating the scale of the recent retreat in semiconductor stocks.

Why Is CoreWeave Stock Dropping?

CoreWeave has emerged as a focal point of concerns surrounding debt-financed artificial intelligence infrastructure.

The cloud computing company provides access to high-performance Nvidia processors and has relied heavily on borrowing to expand its data center operations.

CoreWeave shares fell more than 15% on Wednesday and continued declining during Thursday’s session as investors scrutinized the company’s substantial debt obligations.

Yields on some of CoreWeave’s corporate bonds climbed to distressed levels, highlighting growing concerns about the costs of financing its expansion.

With interest rates remaining elevated, companies dependent on borrowed capital face additional pressure to demonstrate that investments in computing infrastructure can generate sufficient revenue and cash flow.

Why Are AI and Data Center Stocks Falling?

The broader selloff reflects concerns about the extraordinary amount of money being invested in artificial intelligence infrastructure.

Major technology companies are spending billions of dollars on data centers, advanced semiconductors, networking equipment, and energy infrastructure to support increasingly sophisticated AI models.

While demand for computing capacity remains strong, investors are questioning whether future revenue will justify the enormous upfront costs.

There is also an important distinction between companies supplying AI infrastructure and those financing its development.

Semiconductor manufacturers can generate revenue by selling processors and related equipment. Data center operators, meanwhile, must recover substantial construction, equipment, and financing costs through long-term customer contracts.

This difference has become increasingly important as investors evaluate the financial sustainability of the AI investment cycle.

How Interest Rates Are Affecting AI Stocks

Higher borrowing costs are adding another layer of uncertainty for technology companies pursuing aggressive expansion strategies.

Recent inflation reports have increased expectations that the Federal Reserve could raise interest rates further, potentially making debt-financed infrastructure projects more expensive.

For companies with significant borrowing requirements, higher interest expenses can reduce profitability, constrain cash flow, and complicate future investment plans.

These concerns extend beyond AI infrastructure providers. The broader technology sector has experienced renewed volatility as investors reassess valuations and future growth expectations.

Is the AI Stock Selloff a Sign of a Bigger Technology Correction?

The recent decline in AI-related stocks highlights a broader shift in investor sentiment toward high-growth technology companies.

Investors are increasingly distinguishing between businesses demonstrating sustainable revenue growth and those relying on aggressive spending assumptions.

The selloff does not necessarily indicate that demand for artificial intelligence is weakening. Businesses continue adopting AI for automation, data analysis, cybersecurity, and enterprise software.

However, continued adoption does not guarantee that every company involved in the AI industry will generate sufficient profits to justify its valuation.

As technology companies face greater scrutiny, profitability, cash flow, debt levels, and the timing of investment returns may become increasingly important.

What Does the AI Selloff Mean for Small-Cap Technology Stocks?

For small-cap and emerging technology companies, changing market conditions could create both opportunities and challenges.

Businesses developing AI applications, semiconductor components, and infrastructure services may benefit from continued adoption of artificial intelligence.

However, tighter financing conditions could make it more difficult for smaller companies to raise the capital needed to expand operations or commercialize new technologies.

Companies with established customers, recurring revenue, and manageable debt levels may be better positioned to navigate heightened market scrutiny.

The recent volatility suggests that investors are becoming more selective about how companies finance growth and when those investments are expected to generate meaningful returns.

As artificial intelligence continues reshaping the technology industry, the next phase of the AI investment cycle may depend less on spending announcements and more on sustainable profitability and financial discipline.